Research ended
Crinetics Pharmaceuticals, Inc. (CRNX) was acquired by Vertex for $85.00 a share in cash on 2 September 2026.
Our research on Crinetics Pharmaceuticals, Inc. ended on . Once a takeover closes, the shares stop trading under CRNX and there is nothing left to research. The last note, from , is below.
We keep this page so links to it still work and what we published about the stock stays on the record.
The last thesis
Crinetics Pharmaceuticals was acquired by Vertex for $85.00 per share in cash on 1 September 2026 and no longer trades, so the equity story is finished. Atumelnant's Phase 3 enrollment, expected in the first quarter of 2027, is the next marker on the assets.